SG10202011021XA - Dna monoclonal antibodies targeting influenza virus - Google Patents
Dna monoclonal antibodies targeting influenza virusInfo
- Publication number
- SG10202011021XA SG10202011021XA SG10202011021XA SG10202011021XA SG10202011021XA SG 10202011021X A SG10202011021X A SG 10202011021XA SG 10202011021X A SG10202011021X A SG 10202011021XA SG 10202011021X A SG10202011021X A SG 10202011021XA SG 10202011021X A SG10202011021X A SG 10202011021XA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibodies
- influenza virus
- antibodies targeting
- targeting influenza
- dna monoclonal
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332381P | 2016-05-05 | 2016-05-05 | |
| US201662376162P | 2016-08-17 | 2016-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202011021XA true SG10202011021XA (en) | 2020-12-30 |
Family
ID=60203613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809783RA SG11201809783RA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
| SG10202011021XA SG10202011021XA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809783RA SG11201809783RA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting influenza virus |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11851477B2 (es) |
| EP (1) | EP3452504A4 (es) |
| JP (2) | JP7506869B2 (es) |
| KR (3) | KR102375324B1 (es) |
| CN (2) | CN110325546B (es) |
| AU (2) | AU2017261305B2 (es) |
| BR (1) | BR112018072708A2 (es) |
| CA (1) | CA3023093A1 (es) |
| MX (2) | MX2018013521A (es) |
| SG (2) | SG11201809783RA (es) |
| WO (1) | WO2017192946A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190116975A (ko) * | 2016-11-07 | 2019-10-15 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
| AU2022383057A1 (en) * | 2021-11-05 | 2024-05-16 | Abviro Llc | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040087521A1 (en) * | 1993-03-18 | 2004-05-06 | Merck & Co., Inc. | Nucleic acid pharmaceuticals-influenza matrix |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| EP2380976A4 (en) * | 2008-12-25 | 2012-11-07 | Univ Osaka | HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS |
| WO2011041391A1 (en) * | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| EP3812397A1 (en) * | 2011-07-18 | 2021-04-28 | Institute for Research in Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| WO2013114885A1 (en) * | 2012-01-31 | 2013-08-08 | Osaka University | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
| AU2013358944B2 (en) * | 2012-12-13 | 2016-08-18 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
| EP3080159A4 (en) * | 2013-12-13 | 2017-08-02 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| WO2016089862A1 (en) * | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| SG10202009182RA (en) * | 2016-03-21 | 2020-11-27 | David Weiner | Dna antibody constructs and method of using same |
-
2017
- 2017-05-05 CN CN201780042120.XA patent/CN110325546B/zh active Active
- 2017-05-05 WO PCT/US2017/031213 patent/WO2017192946A1/en unknown
- 2017-05-05 US US16/098,921 patent/US11851477B2/en active Active
- 2017-05-05 KR KR1020187035167A patent/KR102375324B1/ko active IP Right Grant
- 2017-05-05 CN CN202410237536.9A patent/CN118109478A/zh active Pending
- 2017-05-05 KR KR1020237027640A patent/KR20230125851A/ko active Application Filing
- 2017-05-05 BR BR112018072708-3A patent/BR112018072708A2/pt unknown
- 2017-05-05 SG SG11201809783RA patent/SG11201809783RA/en unknown
- 2017-05-05 MX MX2018013521A patent/MX2018013521A/es unknown
- 2017-05-05 CA CA3023093A patent/CA3023093A1/en active Pending
- 2017-05-05 SG SG10202011021XA patent/SG10202011021XA/en unknown
- 2017-05-05 KR KR1020227008096A patent/KR20220035288A/ko not_active IP Right Cessation
- 2017-05-05 JP JP2019510570A patent/JP7506869B2/ja active Active
- 2017-05-05 AU AU2017261305A patent/AU2017261305B2/en active Active
- 2017-05-05 EP EP17793413.0A patent/EP3452504A4/en active Pending
-
2018
- 2018-11-05 MX MX2024000118A patent/MX2024000118A/es unknown
-
2022
- 2022-05-11 JP JP2022078109A patent/JP2022116034A/ja active Pending
-
2023
- 2023-11-16 US US18/511,108 patent/US20240150442A1/en active Pending
-
2024
- 2024-05-17 AU AU2024203297A patent/AU2024203297A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017192946A1 (en) | 2017-11-09 |
| AU2017261305A1 (en) | 2018-12-20 |
| WO2017192946A8 (en) | 2018-12-27 |
| JP2022116034A (ja) | 2022-08-09 |
| MX2024000118A (es) | 2024-01-22 |
| AU2017261305B2 (en) | 2024-06-13 |
| JP7506869B2 (ja) | 2024-06-27 |
| SG11201809783RA (en) | 2018-12-28 |
| EP3452504A1 (en) | 2019-03-13 |
| KR20190035614A (ko) | 2019-04-03 |
| EP3452504A4 (en) | 2020-07-29 |
| AU2017261305A8 (en) | 2019-08-08 |
| CN110325546B (zh) | 2024-03-19 |
| JP2019521702A (ja) | 2019-08-08 |
| BR112018072708A2 (pt) | 2019-02-19 |
| KR20230125851A (ko) | 2023-08-29 |
| AU2024203297A1 (en) | 2024-06-13 |
| US11851477B2 (en) | 2023-12-26 |
| US20240150442A1 (en) | 2024-05-09 |
| KR20220035288A (ko) | 2022-03-21 |
| MX2018013521A (es) | 2019-06-10 |
| CA3023093A1 (en) | 2017-11-09 |
| CN118109478A (zh) | 2024-05-31 |
| CN110325546A (zh) | 2019-10-11 |
| KR102375324B1 (ko) | 2022-03-18 |
| US20190135899A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275547A (en) | Antigen-binding proteins target co-antigens | |
| ZA202001285B (en) | Antigen-binding proteins targeting shared antigens | |
| SG10201913505WA (en) | Truncated crispr-cas proteins for dna targeting | |
| CL2018000732A1 (es) | Variantes optimizadas de anticuerpos anti-vegf. | |
| HK1249114A1 (zh) | 針對bcma的單克隆抗體 | |
| ZA201804326B (en) | Therapeutic cd47 antibodies | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| SG10202011027QA (en) | Dna monoclonal antibodies targeting checkpoint molecules | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| GB201601075D0 (en) | Antibodies molecules | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| SG11201605691VA (en) | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen | |
| HK1256816A1 (zh) | 新型抗人gpvi抗體及其用途 | |
| DK3265121T3 (da) | Markørsystem, især for baculovirus-eksprimerede underenhedsantigener | |
| IL275296A (en) | Epstein-Barr virus antigen structures | |
| EP3339439A4 (en) | MONOCLONAL ANTIBODY TO NEUTRALIZE THE INFECTIOUSITY OF ALL EBOLA VIRUSES | |
| SG10202011023YA (en) | Dna monoclonal antibodies targeting il-6 and cd126 | |
| EP3423090C0 (en) | NOVEL INFLUENZA ANTIGENS | |
| SG10202011021XA (en) | Dna monoclonal antibodies targeting influenza virus | |
| SG11201403773WA (en) | Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3 | |
| EP3362093A4 (en) | MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| IL282030A (en) | Antibodies to EPN1 | |
| GB201707106D0 (en) | Viral antigens | |
| GB201707093D0 (en) | Viral antigens |